search
Back to results

Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19 (FASCINATE)

Primary Purpose

COVID-19, COVID-19 Respiratory Infection, Long COVID

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Low-field magnetic resonance imaging
Nailfold capillaroscopy
Spiroergometry
Realtime deformability cytometry
Sponsored by
University of Erlangen-Nürnberg Medical School
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COVID-19 focused on measuring COVID-19, Long COVID, post COVID

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Control arm:

Inclusion Criteria:

  • Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to German recommendations)
  • Long Covid criteria not met according to AWMF S1 guideline

Exclusion Criteria:

  • Acute SARS-CoV-2 infection and need for isolation
  • Necessary quarantine
  • Pregnancy, lactation
  • Indication of acute infection
  • Known pleural or pericardial effusion
  • Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
  • Marked thoracic deformities
  • Previous lung surgery
  • Injuries that do not allow for physical stress testing
  • Refusal of MRI imaging
  • General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
  • History, clinical, or other suspicion of pulmonary disease
  • Current respiratory infection/symptomatology
  • Pain leading to respiratory limitation
  • Inhaled therapy (e.g., steroids or beta-mimetics)
  • Immunosuppression
  • Any condition that may lead to respiratory limitation (e.g., pain disorder)
  • Obesity (>97% of age percentile)

Recovered arm:

Inclusion Criteria:

  • Positive SARS-CoV-2 infection confirmed by PCR
  • Long Covid criteria not met according to AWMF S1 guideline

Exclusion Criteria:

  • Acute SARS-CoV-2 infection and need for isolation
  • Necessary quarantine
  • Pregnancy, lactation
  • Indication of acute infection
  • Known pleural or pericardial effusion
  • Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
  • Marked thoracic deformities
  • Previous lung surgery
  • Injuries that do not allow for physical stress testing
  • Refusal of MRI imaging
  • General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)

Long Covid arm:

Inclusion Criteria:

  • Positive SARS-CoV-2 infection confirmed by PCR
  • Long Covid criteria according to AWMF S1 guideline fulfilled

Exclusion Criteria:

  • Acute SARS-CoV-2 infection and need for isolation
  • Necessary quarantine
  • Pregnancy, lactation
  • Indication of acute infection
  • Known pleural or pericardial effusion
  • Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
  • Marked thoracic deformities
  • Previous lung surgery
  • Injuries that do not allow for physical stress testing
  • Refusal of MRI imaging
  • General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)

Sites / Locations

  • University Hospital ErlangenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Experimental

Arm Label

Control

Recovered

Long Covid

Arm Description

Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)

Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.

Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.

Outcomes

Primary Outcome Measures

Functional lung assessment (LF-MRI)
Change in functional lung parameters

Secondary Outcome Measures

Morphologic lung assessment (LF-MRI)
Morphologic changes in lung parenchyma
Cardiological functional diagnostics (VO2)
Oxygen uptake (VO2)
Cardiological functional diagnostics (VO2max)
Peak oxygen uptake (VO2max)
Cardiological functional diagnostics (VT2)
Ventilatory anaerobic threshold (VT2)
Cardiological functional diagnostics (VCO2)
Carbon dioxide output (VCO2)
Cardiological functional diagnostics (HR)
Heart rate (HR)
Cardiological functional diagnostics (HRR)
Heart Rate Reserve (HRR)
Cardiological functional diagnostics (Breath rate at VAT)
Breath rate at VAT
Cardiological functional diagnostics (BRR)
Breath rate reserve (BRR)
Cardiological functional diagnostics (VE)
Minute ventilation (VE)
Cardiological functional diagnostics (O2Pulse)
O2Pulse
Cardiological functional diagnostics (HRV)
Heart rate variability (HRV)
Cardiological functional diagnostics (Borg Scale)
Exercise capacity nach Borg Scale
Cardiological functional diagnostics (BGA)
Capillary blood gas and lactate (BGA)
Nailfold capillaroscopy (capillaries)
Number of capillaries in first row
Nailfold capillaroscopy (first row)
Number of capillaries in first row
Nailfold capillaroscopy (morphology)
Morphology of capillaries
Blood sample (antibodies)
SARS-CoV2-antibodies
Blood sample (auto antibodies)
Autoantibodies against G-protein receptors
Blood sample (RT-DC)
Realtime deformability cytometry
Blood sample (Blood count)
Blood count
Blood sample (IL-6)
Interleukin-6 (IL-6)
Blood sample (CrP)
C-reactive proteine (CrP)
Blood sample (Calpro)
Calprotectin (Calpro)
Blood sample (Coagulation)
Coagulation factors (Coagulation)

Full Information

First Posted
July 5, 2022
Last Updated
July 5, 2022
Sponsor
University of Erlangen-Nürnberg Medical School
search

1. Study Identification

Unique Protocol Identification Number
NCT05445531
Brief Title
Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19
Acronym
FASCINATE
Official Title
Low-field Magnetic Resonance Imaging to Assess Changes in Pulmonary Function Parameters in Confirmed Pediatric SARS-CoV-2 Infection
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 8, 2022 (Anticipated)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
March 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Erlangen-Nürnberg Medical School

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. These viruses predominantly cause mild colds, but can sometimes cause severe pneumonia and pulmonary skeletal changes. By low-field gastric magnetic resonance imaging (NF-MRI), only a small number of structural, scarring changes were seen in a preliminary study of pediatric and adolescent patients with past SARS-CoV-2 infection. In contrast, however, extensive changes in ventilation and blood flow function of the lungs were seen. The long-term consequences and spontaneous progression of these changes on imaging are completely unclear. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Detailed Description
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia and pulmonary skeletal disease. While the molecular basis for the changes in lung tissue or multi-organ involvement have been described, the age-specific long-term consequences, especially in children and adolescents, remain largely unexplained and misunderstood today. Early publications from the primarily affected Chinese provinces described rather mild, partly asymptomatic courses in children. This is consistent with the observation that the risk of severe COVID-19 disease increases steeply from the age of 70 years, and is also determined by the severity of obesity as well as other risk factors. Developmental expression of tissue factors may be one reason for the relative protection of younger patients from severe courses of the disease. However, it is now becoming increasingly clear that some individuals with milder initial symptoms of COVID-19 may suffer from variable and persistent symptoms for many months after initial infection - this includes children. A modern low-field MRI is located in Erlangen, Germany. This technique has already been used to demonstrate persistent damage to lung tissue in adult patients after COVID-19. The device with a field strength of 0.55 Tesla (T) currently has the world's largest aperture (and is thus particularly suitable for patients with claustrophobia, among other things), a very quiet operating noise, and lower energy absorption in the tissue due to the weaker magnetic field than MRI scanners with 1.5T or 3T. This allows MRI imaging in a very broad pediatric population without the need for sedation. To date, no structural changes were revealed by means of this MRI technique - however, large defects in the area of ventilation and blood flow function of the lung are apparent in specific functional sequences. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, COVID-19 Respiratory Infection, Long COVID
Keywords
COVID-19, Long COVID, post COVID

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
111 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Active Comparator
Arm Description
Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
Arm Title
Recovered
Arm Type
Active Comparator
Arm Description
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
Arm Title
Long Covid
Arm Type
Experimental
Arm Description
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
Intervention Type
Diagnostic Test
Intervention Name(s)
Low-field magnetic resonance imaging
Other Intervention Name(s)
LF-MRI
Intervention Description
Functional and morphologic imaging of the lungs
Intervention Type
Diagnostic Test
Intervention Name(s)
Nailfold capillaroscopy
Intervention Description
Imaging of nailfold microvasculature
Intervention Type
Diagnostic Test
Intervention Name(s)
Spiroergometry
Intervention Description
Cardiopulmonary exercise testing
Intervention Type
Diagnostic Test
Intervention Name(s)
Realtime deformability cytometry
Other Intervention Name(s)
RT-DC
Intervention Description
High-throughput measurement of cell deformability and physical properties
Primary Outcome Measure Information:
Title
Functional lung assessment (LF-MRI)
Description
Change in functional lung parameters
Time Frame
Baseline compared to 6 months
Secondary Outcome Measure Information:
Title
Morphologic lung assessment (LF-MRI)
Description
Morphologic changes in lung parenchyma
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (VO2)
Description
Oxygen uptake (VO2)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (VO2max)
Description
Peak oxygen uptake (VO2max)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (VT2)
Description
Ventilatory anaerobic threshold (VT2)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (VCO2)
Description
Carbon dioxide output (VCO2)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (HR)
Description
Heart rate (HR)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (HRR)
Description
Heart Rate Reserve (HRR)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (Breath rate at VAT)
Description
Breath rate at VAT
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (BRR)
Description
Breath rate reserve (BRR)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (VE)
Description
Minute ventilation (VE)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (O2Pulse)
Description
O2Pulse
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (HRV)
Description
Heart rate variability (HRV)
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (Borg Scale)
Description
Exercise capacity nach Borg Scale
Time Frame
Baseline compared to 6 months
Title
Cardiological functional diagnostics (BGA)
Description
Capillary blood gas and lactate (BGA)
Time Frame
Baseline compared to 6 months
Title
Nailfold capillaroscopy (capillaries)
Description
Number of capillaries in first row
Time Frame
Baseline compared to 6 months
Title
Nailfold capillaroscopy (first row)
Description
Number of capillaries in first row
Time Frame
Baseline compared to 6 months
Title
Nailfold capillaroscopy (morphology)
Description
Morphology of capillaries
Time Frame
Baseline compared to 6 months
Title
Blood sample (antibodies)
Description
SARS-CoV2-antibodies
Time Frame
Baseline compared to 6 months
Title
Blood sample (auto antibodies)
Description
Autoantibodies against G-protein receptors
Time Frame
Baseline compared to 6 months
Title
Blood sample (RT-DC)
Description
Realtime deformability cytometry
Time Frame
Baseline compared to 6 months
Title
Blood sample (Blood count)
Description
Blood count
Time Frame
Baseline compared to 6 months
Title
Blood sample (IL-6)
Description
Interleukin-6 (IL-6)
Time Frame
Baseline compared to 6 months
Title
Blood sample (CrP)
Description
C-reactive proteine (CrP)
Time Frame
Baseline compared to 6 months
Title
Blood sample (Calpro)
Description
Calprotectin (Calpro)
Time Frame
Baseline compared to 6 months
Title
Blood sample (Coagulation)
Description
Coagulation factors (Coagulation)
Time Frame
Baseline compared to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Control arm: Inclusion Criteria: Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to German recommendations) Long Covid criteria not met according to AWMF S1 guideline Exclusion Criteria: Acute SARS-CoV-2 infection and need for isolation Necessary quarantine Pregnancy, lactation Indication of acute infection Known pleural or pericardial effusion Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure) Marked thoracic deformities Previous lung surgery Injuries that do not allow for physical stress testing Refusal of MRI imaging General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.) History, clinical, or other suspicion of pulmonary disease Current respiratory infection/symptomatology Pain leading to respiratory limitation Inhaled therapy (e.g., steroids or beta-mimetics) Immunosuppression Any condition that may lead to respiratory limitation (e.g., pain disorder) Obesity (>97% of age percentile) Recovered arm: Inclusion Criteria: Positive SARS-CoV-2 infection confirmed by PCR Long Covid criteria not met according to AWMF S1 guideline Exclusion Criteria: Acute SARS-CoV-2 infection and need for isolation Necessary quarantine Pregnancy, lactation Indication of acute infection Known pleural or pericardial effusion Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure) Marked thoracic deformities Previous lung surgery Injuries that do not allow for physical stress testing Refusal of MRI imaging General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.) Long Covid arm: Inclusion Criteria: Positive SARS-CoV-2 infection confirmed by PCR Long Covid criteria according to AWMF S1 guideline fulfilled Exclusion Criteria: Acute SARS-CoV-2 infection and need for isolation Necessary quarantine Pregnancy, lactation Indication of acute infection Known pleural or pericardial effusion Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure) Marked thoracic deformities Previous lung surgery Injuries that do not allow for physical stress testing Refusal of MRI imaging General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ferdinand Knieling, MD
Phone
+49913185
Ext
33118
Email
ferdinand.knieling@uk-erlangen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ferdinand Knieling, MD
Organizational Affiliation
University Hospital Erlangen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Erlangen
City
Erlangen
State/Province
Bavaria
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ferdinand Knieling, MD
Phone
+49913185
Ext
33118
Email
ki-forschung@uk-erlangen.de
First Name & Middle Initial & Last Name & Degree
Ferdinand Knieling, MD
First Name & Middle Initial & Last Name & Degree
Rafael Heiß, MD
First Name & Middle Initial & Last Name & Degree
Isabelle Schöffl, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
33046696
Citation
Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, Wechsler ME, Mak ACY, Eng C, Salazar S, Medina V, Wohlford EM, Huntsman S, Nickerson DA, Germer S, Zody MC, Abecasis G, Kang HM, Rice KM, Kumar R, Oh S, Rodriguez-Santana J, Burchard EG, Seibold MA. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020 Oct 12;11(1):5139. doi: 10.1038/s41467-020-18781-2.
Results Reference
background
PubMed Identifier
32413319
Citation
Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J; HCA Lung Biological Network. Electronic address: lung-network@humancellatlas.org; HCA Lung Biological Network. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 May 28;181(5):1016-1035.e19. doi: 10.1016/j.cell.2020.04.035. Epub 2020 Apr 27.
Results Reference
background
PubMed Identifier
32979316
Citation
Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Muhlberger E, Kotton DN. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7. doi: 10.1016/j.stem.2020.09.013. Epub 2020 Sep 18.
Results Reference
background
PubMed Identifier
33278357
Citation
Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD. Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021 Jan 7;184(1):149-168.e17. doi: 10.1016/j.cell.2020.11.025. Epub 2020 Nov 19.
Results Reference
background
PubMed Identifier
32187458
Citation
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-1665. doi: 10.1056/NEJMc2005073. Epub 2020 Mar 18. No abstract available.
Results Reference
background
PubMed Identifier
33442016
Citation
Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.
Results Reference
background
PubMed Identifier
33180746
Citation
Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, Kapp ME, Benjamin JT, Gulleman P, Nichols DS, Braunstein LZ, Hackett A, Koval M, Guttentag SH, Blackwell TS, Webber SA, Banovich NE; Vanderbilt COVID-19 Consortium Cohort; Human Cell Atlas Biological Network; Kropski JA, Sucre JM. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. J Clin Invest. 2021 Jan 4;131(1):e140766. doi: 10.1172/JCI140766.
Results Reference
background
PubMed Identifier
33220447
Citation
Heiss R, Grodzki DM, Horger W, Uder M, Nagel AM, Bickelhaupt S. High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19. Magn Reson Imaging. 2021 Feb;76:49-51. doi: 10.1016/j.mri.2020.11.004. Epub 2020 Nov 18.
Results Reference
background
PubMed Identifier
32556807
Citation
Shelmerdine SC, Lovrenski J, Caro-Dominguez P, Toso S; Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce. Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings. Pediatr Radiol. 2020 Aug;50(9):1217-1230. doi: 10.1007/s00247-020-04726-w. Epub 2020 Jun 18.
Results Reference
background
PubMed Identifier
32291501
Citation
Duan YN, Zhu YQ, Tang LL, Qin J. CT features of novel coronavirus pneumonia (COVID-19) in children. Eur Radiol. 2020 Aug;30(8):4427-4433. doi: 10.1007/s00330-020-06860-3. Epub 2020 Apr 14.
Results Reference
background
PubMed Identifier
32442030
Citation
Steinberger S, Lin B, Bernheim A, Chung M, Gao Y, Xie Z, Zhao T, Xia J, Mei X, Little BP. CT Features of Coronavirus Disease (COVID-19) in 30 Pediatric Patients. AJR Am J Roentgenol. 2020 Dec;215(6):1303-1311. doi: 10.2214/AJR.20.23145. Epub 2020 May 22.
Results Reference
background

Learn more about this trial

Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19

We'll reach out to this number within 24 hrs